Potential Biomarkers for Renal Cell Carcinoma Studied
Two investigational microRNAs (miRNAs)—miR-651 and miR-708—appear to be novel biomarkers for renal cell carcinoma, based on the results of a recent study led by Chunni Zhang, PhD, of Jinling Hospital in Nanjing, China, and colleagues. Their findings were presented at the 69th American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo in San Diego.
“There is no standard serologic biomarker to facilitate diagnosis in patients with [this disease], said Dr. Zhang in a recent press release. “Targeting miR-651 and miR-708 by a genetic approach may provide a novel strategy for the treatment of renal cell carcinoma.”
The investigators measured the concentrations of 754 different miRNAs in blood samples from 33 patients with renal cell carcinoma and 33 healthy normal controls. Blood levels of eight miRNAs were found to be either increased or decreased in those with kidney cancer compared with those without. Of these eight miRNAs, miR-651 and miR-708, which were decreased in the patients with renal cell carcinoma, demonstrated the largest areas under the curve (0.888 and 0.832, respectively). Furthermore, the functions of these two miRNAs suggested they may act as tumor suppressors.